Browse News
Filter News
Found 1,669 articles
-
Keep up with the regulator’s latest rulings on novel drugs and expanded indications, as the second half of 2023 promises some major milestone FDA approvals.
-
GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023
11/16/2023
GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the highlights from its “ACLF Day” held on November 11, 2023 during AASLD The Liver Meeting ® in Boston, MA (USA).
-
PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
11/15/2023
PepGen Inc. today announced the appointment of Howard Mayer, M.D. to the PepGen Board of Directors, effective November 15, 2023.
-
In a late-stage trial, treatment with Ipsen and Genfit’s elafibranor led to high rates of biochemical response and the normalization of alkaline phosphatase levels compared with placebo.
-
Nouscom Raises €67.5 million ($72 million) in Oversubscribed Series C Financing Round
11/14/2023
Nouscom announced the completion of its oversubscribed Series C equity financing raising €67.5 million from a syndicate of renowned international healthcare investors.
-
Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
11/13/2023
Ipsen and Medison Pharma are pleased to announce the Health Canada approval for Bylvay™ for the treatment of pruritus in patients aged 6 months or older with Progressive Familial Intrahepatic Cholestasis, a progressive and life-threatening liver disease.
-
GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine
11/13/2023
Ipsen and GENFIT announced full results from the pivotal Phase III ELATIVE® trial, which are being presented in a late-breaking oral session at the American Association for the Study of Liver Diseases and simultaneously published in New England Journal of Medicine.
-
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine
11/13/2023
Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced full results from the pivotal Phase III ELATIVE® trial, which are being presented in a late-breaking oral session (Abstract #484, Monday, 13 November at 16.45 EST) at the American Association for the Study of Liver Disease (AASLD) and simultaneously published in the New England Journal of Medicine (NEJM).
-
Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023
11/10/2023
Exelixis, Inc. (Nasdaq: EXEL) today announced initial results from an expansion cohort of STELLAR-001 evaluating single-agent zanzalintinib in patients with previously treated clear cell renal cell carcinoma (ccRCC).
-
GENFIT Reports Third Quarter 2023 Financial Information
11/9/2023
Lille ; Cambridge ; Zurich ; November 9, 2023 - GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, announced its cash position as of September 30, 2023 and revenue for the first nine months of 20231.
-
GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023
11/2/2023
GENFIT announced that it will present an update on its scientific and corporate progress at The Liver Meeting® 2023 organized by the American Association for the Study of Liver Diseases, which will take place in Boston, MA from November 10-14, 2023.
-
Merrimack Reports Third Quarter 2023 Financial Results
11/2/2023
Merrimack Pharmaceuticals, Inc. announced its third quarter 2023 financial results for the period ended September 30, 2023.
-
October saw a surge of life science job activity with job applications up 65% from last year as well as a number of a significant layoff announcements.
-
MBX Biosciences Announces Appointment of Michelle Graham as Chief Human Resources Officer
11/1/2023
MBX Biosciences, Inc. announced the appointment of Michelle Graham as Chief Human Resources Officer.
-
Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update
11/1/2023
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2023 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.
-
Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance
10/26/2023
Ipsen, a global specialty-driven biopharmaceutical company, presents its sales performance for the year to date and the third quarter of 2023.
-
IRLAB publishes interim report for the period January-September 2023
10/25/2023
IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson's disease, announced that the company's interim report for the period January-September 2023, has been published.
-
Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023
10/22/2023
Exelixis, Inc. announced detailed results from CABINET, a phase 3 pivotal trial evaluating cabozantinib compared with placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort of patients with advanced pancreatic neuroendocrine tumors and a second cohort of patients with advanced extra-pancreatic NET.
-
Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors
10/16/2023
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, announced the appointment of Jeremy Bender, Ph.D., M.B.A., Teresa Bitetti, M.B.A., and David Meek to its Board of Directors, effective today.
-
Galderma Unveils Bold Ambition in Neuromodulation at Liquid Live Event
10/13/2023
Galderma, the emerging pure-play dermatology category leader, hosts the first edition of its Liquid Live event in Dubai as a chance to discuss with clinicians the future of innovation in the field of neuromodulation as well as showcasing the latest neuromodulators from its aesthetics portfolio.